Literature DB >> 24319100

Dedifferentiation and aberrations of the endolysosomal compartment characterize the early stage of nephropathic cystinosis.

Claudia Raggi1, Alessandro Luciani, Nathalie Nevo, Corinne Antignac, Sara Terryn, Olivier Devuyst.   

Abstract

Nephropathic cystinosis, a lysosomal storage disease caused by mutations in the CTNS gene encoding the lysosomal cystine transporter cystinosin, is characterized by generalized proximal tubule (PT) dysfunction that progresses, if untreated, to end-stage renal disease. The pathogenesis of defective PT cellular transport in nephropathic cystinosis remains unclear. We characterized a recently generated line of C57BL/6 Ctns mice and analyzed endocytic uptake, lysosome function, and dedifferentiation and proliferation markers using primary cultures of PT epithelial cells derived from Ctns(-/-) and Ctns(+/+) littermates. Metabolic studies revealed that Ctns(-/-) mice show a progressive PT dysfunction characterized by low-molecular-weight (LMW) proteinuria, glucosuria and phosphaturia, before structural damage and in the absence of renal failure. These changes are related to decreased expression of the multi-ligand receptors megalin and cubilin and to increased dedifferentiation (ZONAB transcription factor) and proliferation (PCNA and Cyclin D1) rates. Studies on PT cells derived from Ctns(-/-) kidneys confirmed cystine overload, with accumulation of enlarged, dysfunctional lysosomes and reduced expression of endocytic receptors reflected by decreased uptake of specific ligands. These changes were related to a loss of integrity of tight junctions with a nuclear translocation of ZONAB and increased proliferation, as observed in Ctns(-/-) kidneys. These data reveal that the absence of cystinosin in PT cells triggers aberrations of the endolysosomal compartment, transport defects and an abnormal transcription program in the early stage of nephropathic cystinosis. Insights into the early manifestations of cystinosis may offer new targets for intervention, before irreversible renal damage.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24319100     DOI: 10.1093/hmg/ddt617

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  30 in total

1.  First Successful Conception Induced by a Male Cystinosis Patient.

Authors:  Koenraad R Veys; Kathleen W D'Hauwers; Angelique J C M van Dongen; Mirian C Janssen; Martine T P Besouw; Ellen Goossens; Lambert P van den Heuvel; Alex A M M Wetzels; Elena N Levtchenko
Journal:  JIMD Rep       Date:  2017-04-13

2.  Apolipoprotein M modulates erythrocyte efflux and tubular reabsorption of sphingosine-1-phosphate.

Authors:  Iryna Sutter; Rebekka Park; Alaa Othman; Lucia Rohrer; Thorsten Hornemann; Markus Stoffel; Olivier Devuyst; Arnold von Eckardstein
Journal:  J Lipid Res       Date:  2014-06-20       Impact factor: 5.922

Review 3.  Regulation of TFEB activity and its potential as a therapeutic target against kidney diseases.

Authors:  Weihuang Zhang; Xiaoyu Li; Shujun Wang; Yanse Chen; Huafeng Liu
Journal:  Cell Death Discov       Date:  2020-05-01

Review 4.  Chloride transporters and receptor-mediated endocytosis in the renal proximal tubule.

Authors:  Olivier Devuyst; Alessandro Luciani
Journal:  J Physiol       Date:  2015-05-11       Impact factor: 5.182

5.  Cell-Based Phenotypic Drug Screening Identifies Luteolin as Candidate Therapeutic for Nephropathic Cystinosis.

Authors:  Ester De Leo; Mohamed A Elmonem; Sante Princiero Berlingerio; Marine Berquez; Beatrice Paola Festa; Roberto Raso; Francesco Bellomo; Tobias Starborg; Manoe Jacoba Janssen; Zeinab Abbaszadeh; Sara Cairoli; Bianca Maria Goffredo; Rosalinde Masereeuw; Olivier Devuyst; Martin Lowe; Elena Levtchenko; Alessandro Luciani; Francesco Emma; Laura Rita Rega
Journal:  J Am Soc Nephrol       Date:  2020-06-05       Impact factor: 10.121

6.  A mouse model suggests two mechanisms for thyroid alterations in infantile cystinosis: decreased thyroglobulin synthesis due to endoplasmic reticulum stress/unfolded protein response and impaired lysosomal processing.

Authors:  H P Gaide Chevronnay; V Janssens; P Van Der Smissen; X H Liao; Y Abid; N Nevo; C Antignac; S Refetoff; S Cherqui; C E Pierreux; P J Courtoy
Journal:  Endocrinology       Date:  2015-03-26       Impact factor: 4.736

7.  Impact of atypical mitochondrial cyclic-AMP level in nephropathic cystinosis.

Authors:  Francesco Bellomo; Anna Signorile; Grazia Tamma; Marianna Ranieri; Francesco Emma; Domenico De Rasmo
Journal:  Cell Mol Life Sci       Date:  2018-03-16       Impact factor: 9.261

8.  Protection of Cystinotic Mice by Kidney-Specific Megalin Ablation Supports an Endocytosis-Based Mechanism for Nephropathic Cystinosis Progression.

Authors:  Virginie Janssens; Héloïse P Gaide Chevronnay; Sandrine Marie; Marie-Françoise Vincent; Patrick Van Der Smissen; Nathalie Nevo; Seppo Vainio; Rikke Nielsen; Erik I Christensen; François Jouret; Corinne Antignac; Christophe E Pierreux; Pierre J Courtoy
Journal:  J Am Soc Nephrol       Date:  2019-09-23       Impact factor: 10.121

9.  Impaired Lysosomal Function Underlies Monoclonal Light Chain-Associated Renal Fanconi Syndrome.

Authors:  Alessandro Luciani; Christophe Sirac; Sara Terryn; Vincent Javaugue; Jenny Ann Prange; Sébastien Bender; Amélie Bonaud; Michel Cogné; Pierre Aucouturier; Pierre Ronco; Frank Bridoux; Olivier Devuyst
Journal:  J Am Soc Nephrol       Date:  2015-11-27       Impact factor: 10.121

10.  Use of Human Induced Pluripotent Stem Cells and Kidney Organoids To Develop a Cysteamine/mTOR Inhibition Combination Therapy for Cystinosis.

Authors:  Jennifer A Hollywood; Aneta Przepiorski; Randall F D'Souza; Sreevalsan Sreebhavan; Ernst J Wolvetang; Patrick T Harrison; Alan J Davidson; Teresa M Holm
Journal:  J Am Soc Nephrol       Date:  2020-03-20       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.